Cereno Scientific

For the first time, a head-to-head comparison of CS585, a novel IP receptor agonist, was conducted with the FDA-approved IP receptor agonists selexipag and iloprost. The compounds were assessed by direct comparison to elucidate potential differences in selectivity and sustained action. In contrast to the FDA-approved IP receptor agonists (iloprost and selexipag) which showed short-term protection from thrombosis in the laser induced cremaster thrombosis assay in mice, treatment with CS585 resulted in sustained inhibition of clot and fibrin formation in the same model up to 48 hours post-administration. The preclinical results with CS585 thus indicate a favorable profile for inhibiting platelet activation and clot formation and demonstrate a sustained duration of action in mice in the ability to inhibit platelet activation through multiple routes of administration. Importantly, CS585 does not affect coagulation parameters and previous studies demonstrated no potential for increased bleeding in mouse models. Overall, CS585 provides a new option of activating the IP receptor to decrease platelet reactivity and could represent the first viable option for targeting the IP-receptor on platelets for primary inhibition of thrombosis with a reduced risk of bleeding. CS585 was also shown to be more selective for the IP receptor than selexipag and iloprost as determined by platelet aggregation and VASP phosphorylation.

“We are pleased to see this data coming out of our collaboration with the University of Michigan. It is very exciting to see CS585 compared to two FDA-approved drugs and demonstrate more selective and sustained efficacy than currently available IP receptor agonists. This is still in preclinical stage so more testing is needed, however, CS585 shows promise as a potential new approach to the treatment of thrombosis without the risk of bleeding,” said Sten R. Sörensen, CEO, Cereno Scientific.

The abstract presented at the 65th ASH Annual Meeting & Exposition is titled “CS585 Demonstrates Favorable Selectivity and Sustained In Vivo Action in Preventing Platelet Activation and Thrombosis Compared to Existing IP Receptor Agonists”, and was authored by L. Stanger, P. Yalavarthi, S. Lambert, A. Rickenberg, K. Goerger and D. Gilmore at the Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, US; B. Dahlöf and N. Bergh at the University of Gothenburg, Gothenburg, Sweden; and M. Holinstat at the Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, US. The abstract can be found here: https://ash.confex.com/ash/2023/webprogram/Paper186300.html 

There is a growing body of evidence around drug candidate CS585 supporting favorable tolerability and efficacy in preclinical studies. Recently, the drug candidate was published in the top-tier journal Blood showing that CS585 is a highly potent and selective compound given both orally and intravenously and prevents thrombosis for up to 48 hours as observed in preclinical studies. Following the publication, a commentary article and the Blood Podcast highlighted that the new preclinical findings of CS585 could be a significant milestone to improve anti-thrombotic treatment strategies without bleeding.

For further information, please contact:

Tove Bergenholt, Director IR & Communications
Email: tove.bergenholt@cerenoscientific.com
Phone: +46 732-366 246

Sten R. Sörensen, CEO
Email: sten.sorensen@cerenoscientific.com
Phone: +46 73-374 03 74

About Cereno Scientific AB

Cereno Scientific develops innovative treatments for common and rare cardiovascular disease. The lead drug candidate, CS1, is a HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties. A Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with the rare disease pulmonary arterial hypertension (PAH). A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Two initiatives performed during the ongoing Phase II study have shown positive findings suggesting the potential clinical benefit of CS1 in PAH patients. These initial findings are, however, not a guarantee of the final study results that are expected in Q2 2024. Cereno also has two promising preclinical drug candidates in development through research collaborations with the University of Michigan. Investigational drug CS014 is a HDAC inhibitor in development as a treatment for arterial and venous thrombosis prevention. The innovative drug candidate represents a groundbreaking approach to antithrombotic treatment potentially without the associated increased risk of bleeding in humans. CS014 is a new chemical entity with a multi-fold mechanism of action as an epigenetic modulator – regulating platelet activity, fibrinolysis, and clot stability for the prevention of thrombosis without increased risk of bleeding as documented in preclinical studies. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.